Retinoid induced gene
Patent 5776687 Issued on July 7, 1998. Estimated Expiration Date: 
February 28, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
February 28, 2017. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethods of treatment using ciliary neurotrophic factor Patent #: 5648334 InventorsAssigneeApplicationNo. 808303 filed on 02/28/1997US Classes:435/6, Involving nucleic acid424/9.1, IN VIVO DIAGNOSIS OR IN VIVO TESTING424/9.2, Testing efficacy or toxicity of a compound or composition (e.g., drug, vaccine, etc.)435/91.2, Acellular exponential or geometric amplification (e.g., PCR, etc.)536/23.1, DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)536/24.3, Probes for detection of specific nucleotide sequences or primers for the synthesis of DNA or RNA536/24.33PrimersExaminersPrimary: Jones, W. GaryAssistant: Rees, Dianne Attorney, Agent or FirmInternational ClassesC12Q 001/68C12P 019/34 C07H 021/02 C07H 021/04 AbstractA novel human cDNA, called TIG3 (Tazarotene Induced Gene 3), inducible by RAR-selective retinoids and structurally related to a known tumor suppressor gene. Methods of detecting the TIG3 polynucleotide.Other References
Field of SearchInvolving nucleic acidAcellular exponential or geometric amplification (e.g., PCR, etc.) Probes for detection of specific nucleotide sequences or primers for the synthesis of DNA or RNA Primers DNA or RNA fragments or modified forms thereof (e.g., genes, etc.) IN VIVO DIAGNOSIS OR IN VIVO TESTING Testing efficacy or toxicity of a compound or composition (e.g., drug, vaccine, etc.) |
| ||||||||||||||
